Name | N-tert-Butyl-Alpha-phenylnitrone |
Synonyms | PBN Butylphenylnitrone Phenyl N-tert-butylnitrone N-tert-Butyl-Alpha-phenylnitrone N-tert-Butyl-alpha-phenyl nitrone N-benzyliden-tert-butylamine N-ether N-benzylidene-N-tert-butylamine oxide |
CAS | 3376-24-7 |
EINECS | 222-168-6 |
InChI | InChI=1/C11H15NO/c1-11(2,3)12(13)9-10-7-5-4-6-8-10/h4-9H,1-3H3 |
Molecular Formula | C11H15NO |
Molar Mass | 177.24 |
Density | 0.99g/cm3 |
Melting Point | 71-75℃ |
Boling Point | 283.3°C at 760 mmHg |
Flash Point | 118.5°C |
Water Solubility | Soluble in DMSO (10 mg/ml), chloroform (50 mg/ml), and water (20 mg/ml). |
Vapor Presure | 0.00547mmHg at 25°C |
Appearance | Form powder, color white |
pKa | 1.50±0.53(Predicted) |
Storage Condition | Store at <= 20°C. |
Sensitive | Sensitive to air |
Refractive Index | 1.552 |
MDL | MFCD00008799 |
Physical and Chemical Properties | Bioactivity N-tert-Butyl-α-phenylnitrone It is a nitroketone-based free radical scavenger that can form nitric oxide spin adduct. Inhibit the catalytic activity of COX2. It has effective ROS clearance, anti-inflammatory, neuroprotective, anti-aging and anti-diabetic effects, and can penetrate the blood-brain barrier. |
Use | Use spin trapping agent, a Cox-2 inhibitor. |
Safety Description | S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | TX1760000 |
FLUKA BRAND F CODES | 10 |
TSCA | Yes |
HS Code | 2929 90 00 |
solubility | DMSO: soluble |
Merck | 14,7056 |
BRN | 2044028 |
EPA chemical information | 2-Propanamine, 2-methyl-N-(phenylmethylene)-, N-oxide (3376-24-7) |
target
COX-2Reactive oxygen species (ROS)
in vitro study
N-tert-Butyl-α-phenylnitrone (PBN) (25-100 µM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research.
in vivo studies
N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations.